Page 419 - fbkCardioDiabetes_2017

Cardio Diabetes Medicine 2017 395

6. Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramana-
than KB, et al. Comprehensive Cardiovascular Risk Factor Control Improves
Survival: The BARI 2D Trial. J Am CollCardiol. 2015 Aug 18;66(7):765–73.
7. Shroyer AL, Hattler B, Wagner TH, Collins JF, Baltz JH, Quin JA, et al.
Five-Year Outcomes after On-Pump and Off-Pump Coronary-Artery Bypass.
N Engl J Med. 2017 Aug 16;377(7):623–32.
8. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Straka Z, et al.
Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass
Grafting. N Engl J Med. 2016 Oct 23;375(24):2359–68.
9. Diegeler A, Börgermann J, Kappert U, Breuer M, Böning A, Ursulescu A,
et al. Off-Pump versus On-Pump Coronary-Artery Bypass Grafting in Elderly
Patients. N Engl J Med. 2013 Mar 11;368(13):1189–98.
10. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et
al. Drug eluting and bare metal stents in people with and without dia-
betes: collaborative network meta-analysis. England; 2008 Aug p. a1331.
11. Kufner S, de Waha A, Tomai F, Park S-W, Lee S-W, Lim D-S, et al. A
meta-analysis of specifically designed randomized trials of sirolimus-eluting
versus paclitaxel-eluting stents in diabetic patients with coronary artery
disease. Am Heart J. 2011 Oct;162(4):740–7.
Figure 4 : Adopted from Serruys et al (17). The Heart 12. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, et al.
Team and Decision-Making in Complex Coronary Outcomes with various drug eluting or bare metal stents in patients with
Artery Disease. The complex interaction among an- diabetes mellitus: mixed treatment comparison analysis of 22,844 patient
atomic complexity, clinical factors/comorbidities, years of follow-up from randomised trials. BMJ. 2012 Aug 10;345:e5170.
patient wishes, and local resources the heart team 13. Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, et al.
needs to consider in decision-making in patients with Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
N Engl J Med. 2015 Oct 29;373(18):1709–19.
complex coronary artery disease.
14. Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ,
et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass
Conclusion Grafting for Severe Coronary Artery Disease. N Engl J Med. 2009 Mar
Diabetics with CAD have extensive disease and have 5;360(10):961–72.
higher morbidity and mortality related to CV events. 15. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et
Optimal medical therapy with control of 6 RFs (no al. Strategies for multivessel revascularization in patients with diabetes.
smoking, non-high-density lipoprotein cholester- N Engl J Med. 2012 Dec 20;367(25):2375–84.
ol <130 mg/dl, triglycerides <150 mg/dl, blood pres- 16. Park S-J, Ahn J-M, Kim Y-H, Park D-W, Yun S-C, Lee J-Y, et al. Trial of
sure [systolic <130 mm Hg; diastolic <80 mm Hg], Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. N Engl
J Med. 2015 Mar 16;372(13):1204–12.
glycosylated hemoglobin <7%) decreased mortality.
In patients with continued symptoms revasculariza- 17. Serruys PW, Farooq V. Cherry-Picking Historical Data to Legitimize Con-
temporary Practice. J Am CollCardiol. 2017 Jan 23;69(4):404.
tion with CABG or PCI should be considered using a
multi-disciplinary approach. Several non-clinical fac-
tors influence the choice of therapy for these patients
and should be considered on an individualized basis.

References:
1. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med.
2008 Jun 12;358(24):2545–59.
2. Intensive Blood Glucose Control and Vascular Outcomes in Patients with
Type 2 Diabetes. N Engl J Med. 2008 Jun 12;358(24):2560–72.
3. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et
al. Glucose Control and Vascular Complications in Veterans with Type 2
Diabetes. N Engl J Med. 2009 Jan 8;360(2):129–39.
4. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al.
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Athero-
thrombotic Events. N Engl J Med. 2006 Apr 20;354(16):1706–17.
5. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al.
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
N Engl J Med. 2015 Mar 14;372(19):1791–800.

Cardio Diabetes Medicine